Pharma Journalist -

Vanda Pharmaceuticals Inc. (Vanda) provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve…
Read More...

Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease,…
Read More...

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination…
Read More...

BeiGene, Ltd. announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA (tislelizumab) as monotherapy for the treatment of adult patients with unresectable or…
Read More...

Prepare for the definitive meeting dedicated to refining analytics to ensure the swift progression of highly efficacious products through IND and clinical trials, ultimately securing…
Read More...

Valneva SE, a specialty vaccine company, announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the…
Read More...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare,…
Read More...

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) and Wacker Biotech, a contract development and…
Read More...

Nura Bio Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases,…
Read More...

Orbis Medicines, a leader in oral macrocycle drug discovery, announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the…
Read More...